Search

Your search keyword '"D. Parenti"' showing total 31 results

Search Constraints

Start Over You searched for: Author "D. Parenti" Remove constraint Author: "D. Parenti" Topic business.industry Remove constraint Topic: business.industry
31 results on '"D. Parenti"'

Search Results

1. Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study

2. Outcomes of infliximab dose escalation in patients with rheumatoid arthritis

3. Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study

4. AB0754 CLINICALLY MEANINGFUL IMPROVEMENT IN SKIN AND NAIL PSORIASIS IN BIO-NAÏVE ACTIVE PSORIATIC ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB: RESULTS THROUGH WEEK 52 FROM A PHASE-3 STUDY

5. AB0384PROMIS PAIN INTERFERENCE 6B AND FATIGUE 7A SHORT FORMS AND PROFILE-29 IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TNF INHIBITORS

6. SAT0094 UNITED STATES RHEUMATOLOGY PRACTICE-BASED REAL-WORLD EVIDENCE OF METHOTREXATE UTILIZATION AND RESPONSE TO THERAPY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INTRAVENOUS GOLIMUMAB

7. AB0243 Real world clinical trial comparing the patient reported outcomes measurement information system short forms and profiles to cdai disease classification in rheumatoid arthritis patients

8. SAT0346 Clinically meaningful improvement in skin and nail psoriasis in bio-naÏve active psoriatic arthritis patients treated with intravenous golimumab: results through week 24 of the go-vibrant study

9. Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy

10. FRI0211 A descriptive analysis of real-world treatment patterns of innovator infliximab (REMICADE) and biosimilar infliximab in a treatment naÏve turkish rheumatologic disease population

11. SAT0175 A descriptive analysis of real-world treatment patterns in a turkish rheumatology population that continued innovator infliximab (REMICADE) therapy or switched to biosimilar infliximab

12. THU0672 Real world evidence comparing the patient reported outcomes measurement information system to the cdai in rheumatoid arthritis patients

13. Lower-dose diclofenac capsules developed using solumatrix fine particle technology result in clinically meaningful improvements in pain in a phase 3 study of patients with osteoarthritis

14. THU0153 Hemoglobin Is A Better Predictor for Radiographic Progression than Das28 in Patients with Moderate To Severe Rheumatoid Arthritis-Analysis from Intravenously Administered Golimumab Go-Further Study

15. THU0130 Comorbidities and Efficacy of anti-TNF Therapies: History of Depression as A Possible Indicator of Lower Response

16. THU0127 Intravenous Golimumab Therapy Improves Hemoglobin, Resulting in Reduced Anemia, Improved Physical Function and Fatigue in Patients with Moderate To Severe Rheumatoid Arthritis: Results from Go-Further Phase III Clinical Trial

17. AB0316 An Examination of Dose Escalation among Infliximab Users in The US Corrona RA Registry: Table 1

18. AB1036 Updated Results from The Pro Assessment of Inflammatory Arthritis Patients' Experience with IV Administered Biologic Therapy

19. AB0869 Pharmacokinetics and Safety of Lower-Dose Solumatrix® Meloxicam in Healthy Adults

20. THU0336 Lower-Dose Solumatrix® Indomethacin Efficacy in Acute Pain: Results from Two Phase 3 Studies

21. THU0337 Lower-Dose Solumatrix® Indomethacin: Combined Safety Data from Two Phase 3 Studies in Patients with Acute Pain following Elective Surgery: Table 1

22. THU0200 Lower-Dose Solumatrix® Meloxicam: Efficacy and Safety in A Phase 3 Study in Adults with Osteoarthritis Pain

23. Mother-Reported Exposure to Traffic Noise and Sleep Disorders at Six Months of Age in a Birth Cohort Study

24. Mother-reported Exposure to Traffic and the Development of Respiratory Diseases at Six Months of Age in a Birth Cohort Study

25. Mechanism of action of benzydamine in the treatment of oral mucositis

27. Filgrastim (r-mei-HuG-CSF)prevents severe neutropenia & reduces related clinical sequelae in HIV-infected patients:24week,prospective,randomized,controlled trial results

30. A 5 Gc/s parametric reciever for radio astronomy

31. A phase 3 randomized controlled trial of lower-dose diclofenac capsules in patients with osteoarthritis pain: impact on patient-reported outcomes

Catalog

Books, media, physical & digital resources